The Artificial Intelligence in Drug Discovery market is projected to reach $8.95 billion by 2030, at a CAGR of 27.2% from 2023 to 2030. Pharmaceutical companies face several challenges during drug development, including timelines, high investment in R&D, and regulatory challenges. The need for developing and manufacturing advanced therapies has increased, resulting in newer challenges such as the collection and analysis of large data, the need for qualified professionals, and data security. Artificial intelligence (AI) is the replication of human intelligence processes. The use of AI has been increasing in various sectors, especially in the pharmaceutical industry. AI is used in R&D, drug development, diagnosis, disease prevention, remote monitoring, and epidemic prediction in the pharmaceutical industry. The adoption of AI in pharmaceutical drug discovery has enabled better success rates, quicker & faster delivery processes, and access to new biology.
The growth of the AI in drug discovery market is attributed to the rising focus on reducing the turnaround time in drug discovery, growing applications of AI in drug discovery, the rising incidence of chronic diseases, and the high risk of emerging infectious diseases. The rising adoption of machine learning (ML) in drug discovery, the emergence of local and regional start-ups in AI in drug discovery, and rising investments in R&D are creating opportunities for the growth of this market.
The Rise in the Incidence of Chronic Diseases Propels the Need for Artificial Intelligence (AI) in Drug Discovery
The incidence of chronic diseases, including chronic obstructive pulmonary disease (COPD), diabetes, coronary artery disease, hepatitis, arthritis, and cancer, is rising. According to the Centers for Disease Control and Prevention (CDC) data published in December 2022, six in ten adults in the U.S. have a chronic disease. Furthermore, according to the European Commission, in 2021, over 35.2% of the people in the European Union were reported to have chronic diseases.
According to the International Diabetes Federation, in 2020, 502 million people worldwide were diagnosed with diabetes. By 2030, 23.4 million new cases of cancer are expected to develop annually. Among all cancer types, lung cancer is the most common form leading to mortality in Asia-Pacific. Apart from cancer, the prevalence of several additional diseases has also increased over the years. Thus, the high prevalence of chronic diseases is driving the development and manufacturing of advanced therapies, boosting the applications of AI in drug discovery.
Click here to: Get Free Sample Copy of this report
The Rise in the Investments for Artificial Intelligence in Drug Discovery Creates Opportunity for this Market
After significant advancements in AI, its applications in drug discovery are rising. This is indicated by the increasing investments and a rise in the number of collaborations between pharmaceutical industries and AI companies. According to Stanford University’s Institute for Human-Centered Artificial Intelligence’s (HAI) Artificial Intelligence Index, investments in AI in drug discovery reached USD 13.8 billion in 2020. In April 2021, Exscientia (U.K.), a clinical-stage pharma tech company using artificial intelligence (AI) to design patient-based drugs, completed USD 225 million Series D funding round to continue expanding its proprietary pipeline and end-to-end AI drug discovery capabilities.
Based on offering, in 2023, the software segment is expected to account for the largest share of this market
In 2023, the software segment is expected to account for the largest share of the AI in drug discovery market. AI in drug discovery software is used for faster, efficient, and cost-effective drug discovery and enhanced clinical trials. Thus, the growing interest of pharmaceutical companies in developing novel therapies has increased the adoption of AI in drug discovery software.
Based on deployment mode, the cloud-based segment is projected to register the highest CAGR over the forecast period
The cloud-based segment is projected to register the highest CAGR over the forecast period. The demand for cloud-based and web-based platforms is growing due to the benefits of cloud-based models in terms of security and flexibility, high-capacity data storage, quick accessibility, and cost-effectiveness.
Based on application, in 2023, the lead compound identification segment is expected to account for the largest share of this market
In 2023, the lead compound identification segment is expected to account for the largest share of the AI in drug discovery market. The large market share of this segment is attributed to the benefits and importance of lead compound identification in drug discovery. Lead compound identification is a crucial step in drug discovery which is likely to finalize the compounds in drug discovery to reach lead compound optimization and, ultimately, to the clinical candidate development phase. Additionally, the use of AI in lead compound identification helps minimize time and cost.
Based on therapeutic area, in 2023, the oncology segment is expected to account for the largest share of this market
In 2023, the oncology segment is expected to account for the largest share of the AI in drug discovery market. Most drug discovery companies focus on oncology for the drug discovery process. The high prevalence of cancer and the availability of funding for oncology research are the factors contributing to the large market share of this segment. Furthermore, a large number of collaborations between pharmaceutical companies and AI companies is also contributing to this segment’s large market share.
Based on end user, in 2023, the pharmaceutical & biotechnological companies segment is expected to account for the largest share of this market
Pharmaceutical and biopharmaceutical companies are employing AI to find new drugs. These companies focus on reducing operating costs associated with the production of drugs and accelerating the introduction of new treatments to the market. Pharmaceutical companies are under pressure to find new drugs due to the rising burden of chronic and infectious diseases. Thus, pharmaceutical and biopharmaceutical companies are integrating AI into drug research to speed up drug discovery while reducing costs and time to market.
Asia-Pacific: Fastest growing regional market
The emerging infrastructure for AI and pharmaceutical research in countries such as China, India, Singapore, and South Korea, rising funding for cancer research, and growing investments in AI are driving the growth of the AI in drug discovery market in Asia-Paicifc. Furthermore, the growing number of AI-based drug discovery startups is also boosting the growth of this market.
Key Players
The report includes a competitive landscape based on an extensive assessment of the key strategic developments adopted by key market players over the past few years. The key players profiled in the global AI in drug discovery market report are Microsoft Corporation (U.S.), Exscientia plc (U.K.), NVIDIA Corporation (U.S.), Schrödinger, LLC (U.S.), Atomwise, Inc. (U.S.), BenevolentAI Limited (U.K.), Deep Genomics Incorporated (Canada), InSilico Medicine (U.S.), Cloud Pharmaceuticals, Inc. (U.S.), and Standigm Inc. (South Korea).
Scope of the Report
Artificial Intelligence in Drug Discovery Market, by Offering
Artificial Intelligence in Drug Discovery Market, by Deployment Mode
Artificial Intelligence in Drug Discovery Market, by Application
Artificial Intelligence in Drug Discovery Market, by Therapeutic Area
Artificial Intelligence in Drug Discovery Market, by End User
Artificial Intelligence in Drug Discovery Market, by Geography
Key questions answered in the report:
This study offers a detailed assessment of the AI in drug discovery market and includes the market size & forecast for various segmentations such as offering, deployment mode, therapeutic area, application, and end user. The AI in drug discovery market study also involves the value analysis of various segments of the AI in drug discovery market at regional and country levels.
The global AI in drug discovery market is projected to reach $8.95 billion by 2030, at a CAGR of 27.2% during the forecast period.
Based on offering, in 2023, the software segment is expected to account for the largest share. Recurring revenue from the companies owing to the subscription-based or licensing models offered by the software companies are the factors attributed to the large market share of this segment.
Based on deployment mode, the cloud & web-based segment is projected to register the highest CAGR over the forecast period. Growing preference for cloud-based and web-based models owing to their advantages contribute to the growth of this market.
The growth of the AI in drug discovery market is attributed to the rising focus on reducing the turnaround time in drug discovery, growing applications of AI in drug discovery, the rising incidence of chronic diseases, and the high risk of emerging infectious diseases. The rising adoption of machine learning (ML) in drug discovery, the emergence of local and regional start-ups in AI in drug discovery, and increasing investments in R&D are also creating opportunities for market growth.
The key players profiled in the global AI in drug discovery market are Microsoft Corporation (U.S.), Exscientia plc (U.K.), NVIDIA Corporation (U.S.), Schrödinger, LLC (U.S.), Atomwise, Inc. (U.S.), BenevolentAI Limited. (U.K.), Deep Genomics Incorporated (Canada), InSilico Medicine (U.S.), Cloud Pharmaceuticals, Inc. (U.S.), and Standigm Inc. (South Korea).
Emerging economies like China and India are projected to offer significant growth opportunities to the market players due to the availability of infrastructure for drug discovery research, leading to the growing adoption of AI in drug discovery in these countries.
This report provides pre & post COVID-19 market estimates.
1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-up Approach
2.3.1.2. Top-down Approach
2.3.1.3. Growth Forecast
2.3.2. Market Share Analysis
2.4. Assumptions for the Study
2.5. Limitations for the Study
3. Executive Summary
4. Market Insights
4.1. Introduction
4.2. Drivers
4.2.1. Rising Focus on Reducing Turnaround Time in Drug Discovery
4.2.2. Growing Applications of AI in Drug Discovery
4.2.3. Rising Incidences of Chronic Diseases
4.2.4. Rising Collaborations and Partnerships to Accelerate the Drug Discovery and Development
4.3. Restraints
4.3.1. Limited Availability of Resources for Integration of AI in Drug Discovery
4.4. Opportunity
4.4.1. Emerging Economies
4.4.2. Rise in the Investments for R&D
4.5. Challenges
4.5.1. Limited Availability of Data Setss
4.6. Impact of COVID-19 on the AI in Drug Discovery Market
5. Global AI in Drug Discovery Market, by Offering
5.1. Introduction
5.2. Software
5.3. Services
6. Global AI in Drug Discovery Market, by Deployment Mode
6.1. Introduction
6.2. Cloud & Web-based Mode
6.3. On-premises Mode
7. Global AI in Drug Discovery Market, by Application
7.1. Introduction
7.2. Target Discovery & Validation
7.3. Lead Compound Identification
7.4. De Novo Design & Drug Optimization
7.5. Preclinical & Clinical Testing
8. Global AI in Drug Discovery Market, by Therapeutic Area
8.1. Introduction
8.2. Oncology
8.3. Neurodegenerative Diseases
8.4. Cardiovascular Diseases
8.5. Metabolic Diseases
8.6. Other Therapeutic Areas
9. Global AI in Drug Discovery Market, by End User
9.1. Introduction
9.2. Pharmaceutical & Biotechnology Companies
9.3. Contract Research Organizations (CROs)
9.4. Academic & Research Institutes
10. AI in Drug Discovery Market, by Geography
10.1. Introduction
10.2. North America
10.2.1. U. S.
10.2.2. Canada
10.3. Europe
10.3.1. Germany
10.3.2. France
10.3.3. U.K.
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Rest of Asia-Pacific
10.5. Latin America
10.5.1. Brazil
10.5.2. Mexico
10.5.3. Rest of Latin America
10.6. Middle East & Africa
11. Competitive Landscape
11.1. Introduction
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Market Share Analysis (2022)
12. Company Profiles (Business Overview, Financial Overview, Solutions Portfolio, and Strategic Developments)
12.1. Microsoft Corporation
12.2. Exscientia plc
12.3. NVIDIA Corporation
12.4. Schrödinger, LLC
12.5. Atomwise, Inc.
12.6. BenevolentAI Limited
12.7. Deep Genomics Incorporated
12.8. InSilico Medicine
12.9. Cloud Pharmaceuticals, Inc.
12.10. Standigm Inc.
13. Appendix
13.1. Questionnaire
13.2. Available Customization
List of Tables
Table 1 Global AI in Drug Discovery Market Drivers: Impact Analysis (2023–2030)
Table 2 Global AI in Drug Discovery Market Restraints: Impact Analysis (2023–2030)
Table 3 Global AI in Drug Discovery Market Size, by Offering, 2021–2030 (USD Million)
Table 4 Global AI in Drug Discovery Software Market Size, by Country/Region, 2021–2030 (USD Million)
Table 5 Global AI in Drug Discovery Services Market Size, by Country/Region, 2021–2030 (USD Million)
Table 6 Global AI in Drug Discovery Market Size, by Deployment Mode, 2021–2030 (USD Million)
Table 7 Global AI in Drug Discovery Market Size for Cloud & Web-Based Mode, by Country/Region, 2021–2030 (USD Million)
Table 8 Global AI in Drug Discovery Market Size for On-Premises Mode, by Country/Region, 2021–2030 (USD Million)
Table 9 Global AI in Drug Discovery Market Size, by Application, 2021–2030 (USD Million)
Table 10 Global AI in Drug Discovery Market Size for Target Discovery & validation, by Country/Region, 2021–2030 (USD Million)
Table 11 Global AI in Drug Discovery Market Size for Lead Compound Identification, by Country/Region, 2021–2030 (USD Million)
Table 12 Global AI in Drug Discovery Market Size for De Novo Design and Drug Optimization, by Country/Region, 2021–2030 (USD Million)
Table 13 Global AI in Drug Discovery Market Size for Preclinical & Clinical Testing, by Country/Region, 2021–2030 (USD Million)
Table 14 Global AI in Drug Discovery Market Size, by Therapeutic Area, 2021–2030 (USD Million)
Table 15 Global AI in Drug Discovery Market Size for Oncology, by Country/Region, 2021–2030 (USD Million)
Table 16 Global AI in Drug Discovery Market Size for Neurodegenerative Diseases, by Country/Region, 2021–2030 (USD Million)
Table 17 Global AI in Drug Discovery Market Size for Cardiovascular Diseases, by Country/Region, 2021–2030 (USD Million)
Table 18 Global AI in Drug Discovery Market Size for Metabolic Diseases, by Country/Region, 2021–2030 (USD Million)
Table 19 Global AI in Drug Discovery Market Size for Other Therapeutic Areas, by Country/Region, 2021–2030 (USD Million)
Table 20 Global AI in Drug Discovery Market Size, by End User, 2021–2030 (USD Million)
Table 21 Global AI in Drug Discovery Market Size for Pharmaceutical & Biotechnology Companies, by Country/Region, 2021–2030 (USD Million)
Table 22 Global AI in Drug Discovery Market Size for Contract Research Organizations (CROs), by Country/Region, 2021–2030 (USD Million)
Table 23 Global AI in Drug Discovery Market Size for Academic & Research Institutes, by Country/Region, 2021–2030 (USD Million)
Table 24 Global AI in Drug Discovery Market Size, by Country/Region, 2021–2030 (USD Million)
Table 25 North America: AI in Drug Discovery Market Size, by Country, 2021–2030 (USD Million)
Table 26 North America: AI in Drug Discovery Market Size, by Offering, 2021–2030 (USD Million)
Table 27 North America: AI in Drug Discovery Market Size, by Deployment Mode, 2021–2030 (USD Million)
Table 28 North America: AI in Drug Discovery Market Size, by Therapeutic Area, 2021–2030 (USD Million)
Table 29 North America: AI in Drug Discovery Market Size, by Application, 2021–2030 (USD Million)
Table 30 North America: AI in Drug Discovery Market Size, by End User, 2021–2030 (USD Million)
Table 31 U.S.: AI in Drug Discovery Market Size, by Offering, 2021–2030 (USD Million)
Table 32 U.S.: AI in Drug Discovery Market Size, by Deployment Mode, 2021–2030 (USD Million)
Table 33 U.S.: AI in Drug Discovery Market Size, by Therapeutic Area, 2021–2030 (USD Million)
Table 34 U.S.: AI in Drug Discovery Market Size, by Application, 2021–2030 (USD Million)
Table 35 U.S.: AI in Drug Discovery Market Size, by End User, 2021–2030 (USD Million)
Table 36 Canada.: AI in Drug Discovery Market Size, by Offering, 2021–2030 (USD Million)
Table 37 Canada: AI in Drug Discovery Market Size, by Deployment Mode, 2021–2030 (USD Million)
Table 38 Canada: AI in Drug Discovery Market Size, by Therapeutic Area, 2021–2030 (USD Million)
Table 39 Canada: AI in Drug Discovery Market Size, by Application, 2021–2030 (USD Million)
Table 40 Canada.: AI in Drug Discovery Market Size, by End User, 2021–2030 (USD Million)
Table 41 Europe: AI in Drug Discovery Market Size, by Country/Region, 2023–2030 (USD Million))
Table 42 Europe: AI in Drug Discovery Market Size, by Offering, 2021–2030 (USD Million)
Table 43 Europe: AI in Drug Discovery Market Size, by Deployment Mode, 2021–2030 (USD Million)
Table 44 Europe: AI in Drug Discovery Market Size, by Therapeutic Area, 2021–2030 (USD Million)
Table 45 Europe: AI in Drug Discovery Market Size, by Application, 2021–2030 (USD Million)
Table 46 Europe: AI in Drug Discovery Market Size, by End User, 2021–2030 (USD Million)
Table 47 Germany: AI in Drug Discovery Market Size, by Offering, 2021–2030 (USD Million)
Table 48 Germany: AI in Drug Discovery Market Size, by Deployment Mode, 2021–2030 (USD Million)
Table 49 Germany: AI in Drug Discovery Market Size, by Therapeutic Area, 2021–2030 (USD Million)
Table 50 Germany: AI in Drug Discovery Market Size, by Application, 2021–2030 (USD Million)
Table 51 Germany: AI in Drug Discovery Market Size, by End User, 2021–2030 (USD Million)
Table 52 France: AI in Drug Discovery Market Size, by Offering, 2021–2030 (USD Million)
Table 53 France: AI in Drug Discovery Market Size, by Deployment Mode, 2021–2030 (USD Million)
Table 54 France: AI in Drug Discovery Market Size, by Therapeutic Area, 2021–2030 (USD Million)
Table 55 France: AI in Drug Discovery Market Size, by Application, 2021–2030 (USD Million)
Table 56 France: AI in Drug Discovery Market Size, by End User, 2021–2030 (USD Million)
Table 57 U.K.: AI in Drug Discovery Market Size, by Offering, 2021–2030 (USD Million)
Table 58 U.K.: AI in Drug Discovery Market Size, by Deployment Mode, 2021–2030 (USD Million)
Table 59 U.K.: AI in Drug Discovery Market Size, by Therapeutic Area, 2021–2030 (USD Million)
Table 60 U.K.: AI in Drug Discovery Market Size, by Application, 2021–2030 (USD Million)
Table 61 U.K.: AI in Drug Discovery Market Size, by End User, 2021–2030 (USD Million)
Table 62 Italy: AI in Drug Discovery Market Size, by Offering, 2021–2030 (USD Million)
Table 63 Italy: AI in Drug Discovery Market Size, by Deployment Mode, 2021–2030 (USD Million)
Table 64 Italy: AI in Drug Discovery Market Size, by Therapeutic Area, 2021–2030 (USD Million)
Table 65 Italy: AI in Drug Discovery Market Size, by Application, 2021–2030 (USD Million)
Table 66 Italy: AI in Drug Discovery Market Size, by End User, 2021–2030 (USD Million)
Table 67 Spain: AI in Drug Discovery Market Size, by Offerings, 2021–2030 (USD Million)
Table 68 Spain: AI in Drug Discovery Market Size, by Deployment Mode, 2021–2030 (USD Million)
Table 69 Spain: AI in Drug Discovery Market Size, by Therapeutic Area, 2021–2030 (USD Million)
Table 70 Spain: AI in Drug Discovery Market Size, by Application, 2021–2030 (USD Million)
Table 71 Spain: AI in Drug Discovery Market Size, by End User, 2021–2030 (USD Million)
Table 72 Rest of Europe: AI in Drug Discovery Market Size, by Offering, 2021–2030 (USD Million)
Table 73 Rest of Europe: AI in Drug Discovery Market Size, by Deployment Mode, 2021–2030 (USD Million)
Table 74 Rest of Europe: AI in Drug Discovery Market Size, by Therapeutic Area, 2021–2030 (USD Million)
Table 75 Rest of Europe: AI in Drug Discovery Market Size, by Application, 2021–2030 (USD Million)
Table 76 Rest of Europe: AI in Drug Discovery Market Size, by End User, 2021–2030 (USD Million)
Table 77 Asia-Pacific: AI in Drug Discovery Market Size, by Country/Region, 2021–2030 (USD Million)
Table 78 Asia-Pacific: AI in Drug Discovery Market Size, by Offering, 2021–2030 (USD Million)
Table 79 Asia-Pacific: AI in Drug Discovery Market Size, by Deployment Mode, 2021–2030 (USD Million)
Table 80 Asia-Pacific: AI in Drug Discovery Market Size, by Therapeutic Area, 2021–2030 (USD Million)
Table 81 Asia-Pacific: AI in Drug Discovery Market Size, by Application, 2021–2030 (USD Million)
Table 82 Asia-Pacific: AI in Drug Discovery Market Size, by End User, 2021–2030 (USD Million)
Table 83 China: AI in Drug Discovery Market Size, by Offering, 2021–2030 (USD Million)
Table 84 China: AI in Drug Discovery Market Size, by Deployment Mode, 2021–2030 (USD Million)
Table 85 China: AI in Drug Discovery Market Size, by Therapeutic Area, 2021–2030 (USD Million)
Table 86 China: AI in Drug Discovery Market Size, by Application, 2021–2030 (USD Million)
Table 87 China: AI in Drug Discovery Market Size, by End User, 2021–2030 (USD Million)
Table 88 Japan: AI in Drug Discovery Market Size, by Offering, 2021–2030 (USD Million)
Table 89 Japan: AI in Drug Discovery Market Size, by Deployment Mode, 2021–2030 (USD Million)
Table 90 Japan: AI in Drug Discovery Market Size, by Therapeutic Area, 2021–2030 (USD Million)
Table 91 Japan: AI in Drug Discovery Market Size, by Application, 2021–2030 (USD Million)
Table 92 Japan: AI in Drug Discovery Market Size, by End User, 2021–2030 (USD Million)
Table 93 India: AI in Drug Discovery Market Size, by Offering, 2021–2030 (USD Million)
Table 94 India: AI in Drug Discovery Market Size, by Deployment Mode, 2021–2030 (USD Million)
Table 95 India: AI in Drug Discovery Market Size, by Therapeutic Area, 2021–2030 (USD Million)
Table 96 India: AI in Drug Discovery Market Size, by Application, 2021–2030 (USD Million)
Table 97 India: AI in Drug Discovery Market Size, by End User, 2021–2030 (USD Million)
Table 98 Rest of Asia Pacific: AI in Drug Discovery Market Size, by Offering, 2021–2030 (USD Million)
Table 99 Rest of Asia Pacific: AI in Drug Discovery Market Size, by Deployment Mode, 2021–2030 (USD Million)
Table 100 Rest of Asia Pacific: AI in Drug Discovery Market Size, by Therapeutic Area, 2021–2030 (USD Million)
Table 101 Rest of Asia Pacific: AI in Drug Discovery Market Size, by Application, 2021–2030 (USD Million)
Table 102 Rest of Asia Pacific: AI in Drug Discovery Market Size, by End User, 2021–2030 (USD Million)
Table 103 Latin America: AI in Drug Discovery Market Size, by Country/Region, 2020-2029 (USD Million)
Table 104 Latin America: AI in Drug Discovery Market Size, by Offering, 2021–2030 (USD Million)
Table 105 Latin America: AI in Drug Discovery Market Size, by Deployment Mode, 2021–2030 (USD Million)
Table 106 Latin America: AI in Drug Discovery Market Size, by Therapeutic Area, 2021–2030 (USD Million)
Table 107 Latin America: AI in Drug Discovery Market Size, by Application, 2021–2030 (USD Million)
Table 108 Latin America: AI in Drug Discovery Market Size, by End User, 2021–2030 (USD Million)
Table 109 Brazil: AI in Drug Discovery Market Size, by Offering, 2021–2030 (USD Million)
Table 110 Brazil: AI in Drug Discovery Market Size, by Deployment Mode, 2021–2030 (USD Million)
Table 111 Brazil: AI in Drug Discovery Market Size, by Therapeutic Area, 2021–2030 (USD Million)
Table 112 Brazil: AI in Drug Discovery Market Size, by Application, 2021–2030 (USD Million)
Table 113 Brazil: AI in Drug Discovery Market Size, by End User, 2021–2030 (USD Million)
Table 114 Mexico: AI in Drug Discovery Market Size, by Offering, 2021–2030 (USD Million)
Table 115 Mexico: AI in Drug Discovery Market Size, by Deployment Mode, 2021–2030 (USD Million)
Table 116 Mexico: AI in Drug Discovery Market Size, by Therapeutic Area, 2021–2030 (USD Million)
Table 117 Mexico: AI in Drug Discovery Market Size, by Application, 2021–2030 (USD Million)
Table 118 Mexico: AI in Drug Discovery Market Size, by End User, 2021–2030 (USD Million)
Table 119 Rest of Latin America: AI in Drug Discovery Market Size, by Offering, 2021–2030 (USD Million)
Table 120 Rest of Latin America: AI in Drug Discovery Market Size, by Deployment Mode, 2021–2030 (USD Million)
Table 121 Rest of Latin America: AI in Drug Discovery Market Size, by Therapeutic Area, 2021–2030 (USD Million)
Table 122 Rest of Latin America: AI in Drug Discovery Market Size, by Application, 2021–2030 (USD Million)
Table 123 Rest of Latin America: AI in Drug Discovery Market Size, by End User, 2021–2030 (USD Million)
Table 124 Middle East & Africa: AI in Drug Discovery Market Size, by Offering, 2021–2030 (USD Million)
Table 125 Middle East & Africa: AI in Drug Discovery Market Size, by Deployment Mode, 2021–2030 (USD Million)
Table 126 Middle East & Africa: AI in Drug Discovery Market Size, by Therapeutic Area, 2021–2030 (USD Million)
Table 127 Middle East & Africa: AI in Drug Discovery Market Size, by Application, 2021–2030 (USD Million)
Table 128 Middle East & Africa: AI in Drug Discovery Market Size, by End User, 2021–2030 (USD Million)
Table 129 Recent Developments, by Company, 2020–2022
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 6 Market Size Estimation
Figure 7 Global AI in Drug Discovery Market Size, by Offering, 2023–2030 (USD Million)
Figure 8 Global AI in Drug Discovery Market Size, by Deployment Mode, 2023–2030 (USD Million)
Figure 9 Global AI in Drug Discovery Market Size, by Therapeutic Area, 2023–2030 (USD Million)
Figure 10 Global AI in Drug Discovery Market Size, by Application, 2023–2030 (USD Million)
Figure 11 Global AI in Drug Discovery Market Size, by End User, 2023–2030 (USD Million)
Figure 12 Global AI in Drug Discovery Market, by Geography
Figure 13 Market Dynamics: AI in Drug Discovery Market
Figure 14 Global AI in Drug Discovery Market Size, by Offering, 2023–2030 (USD Million)
Figure 15 Global AI in Drug Discovery Market Size, by Deployment Mode, 2023–2030 (USD Million)
Figure 16 Global AI in Drug Discovery Market Size, by Therapeutic Area, 2023–2030 (USD Million)
Figure 17 Global AI in Drug Discovery Market Size, by Application, 2023–2030 (USD Million)
Figure 18 Global AI in Drug Discovery Market Size, by End User, 2023–2030 (USD Million)
Figure 19 Global AI in Drug Discovery Market Size, by Geography, 2023–2030 (USD Million)
Figure 20 North America: AI in Drug Discovery Market Snapshot
Figure 21 Europe: AI in Drug Discovery Market Size Snapshot
Figure 22 Asia-Pacific: AI in Drug Discovery Market Size Snapshot
Figure 23 Latin America: AI in Drug Discovery Market Size Snapshot
Figure 24 Key Growth Strategies Adopted by Leading Players, 2020–2022
Figure 25 AI in Drug Discovery Market: Competitive Benchmarking by Offering
Figure 26 AI in Drug Discovery Market: Competitive Benchmarking by Geography
Figure 27 Market Share Analysis: AI in Drug Discovery Market, 2022
Figure 28 Microsoft Corporation: Financial Overview (2021)
Figure 29 Exscientia plc: Financial Overview (2021)
Figure 30 NVIDIA Corporation: Financial Overview (2021)
Figure 31 Schrödinger, LLC: Financial Overview (2021)
Figure 32 BenevolentAI Limited: Financial Overview (2021)
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Feb-2023
Published Date: Nov-2022
